# Effect of esculentoside A on autoimmunity in mice and its possible mechanisms<sup>1</sup>

XIAO Zhen-Yu², ZHENG Qin-Yue, ZHANG Jun-Ping, JIANG Yuan-Ying, YI Yang-Hua³ (Department of Pharmacology, ³Department of Medical Chemistry of Natural Products, Second Military Medical University, Shanghai 200433, China)

**KEY WORDS** esculentoside A; autoimmunity; inflammation; intercellular adhesion molecule-1; apoptosis; rheumatoid arthritis

#### ABSTRACT

AIM: To investigate the influence of esculentoside A (EsA) on autoimmunity in mice and its possible mechanisms. METHODS: The level of anti-ds DNA antibody, proliferation of lymphoid cells, inflammation by pathologic section of joint in mice were examined. The autoimmunity model is made through immunizing mice with formaldehyde treated Campylobacter jejuni strain CJ-S131 and Freund's complete adjuvant. The apoptosis of T cell was analyzed through morphology and flow cytometry (FACS). expression of ICAM-1 mRNA in human umbilical vein endothelial cell line (ECV304) was determined by coupled reverse transcription and PCR amplification (RT-PCR). RESULTS: EsA could potently lower the level of anti-ds DNA antibody, inhibit the proliferation of lymphoid cells, and ameliorate inflammation in the joint of model mouse. The apoptosis of thymocyte activated by ConA was markedly accelerated while the expression of ICAM-1 mRNA in ECV304 was decreased by EsA. CONCLUSION: EsA has the positive curative effect on autoimmunity in a mouse model, which may function through inhibition of expression of ICAM-1 mRNA in ECV304 and acceleration of thymocyte apoptosis.

#### INTRODUCTION

China, No 39470814.

Esculentoside A (EsA), a kind of saponin isolated

<sup>1</sup> Project supported by the National Natural Science Foundation of

Phn 86-21-2507-0349. E-mail zhyxiao@yahoo.com Received 2001-11-28 Accepted 2002-04-22

cytokines (2-7). It is generally accepted that many immune cells and cytokines are involved in the occurrence and progress of autoimmune diseases. The previous results showed that EsA possessed therapeutic effect on an autoimmune disease, passive Heymann nephritis<sup>(8)</sup>. We supposed that EsA might have favorable effect in the treatment of autoimmunity. Autoimmune diseases represent an immune attack on self-tissue characterized with the production of autoantibody, inflammation, proliferation of lymphoid tissues, and glomerulonephritis caused by immune To gain a better understanding of the complexes. pharmacological effects of EsA, a model of autoimmunity was established through immunizing mice with formaldehyde treated Campylobacter jejuni strain CJ-S131 and Freund's complete adjuvant. After the positive results

## MATERIALS AND METHODS

thymocyte activated by ConA.

**Reagents** Inactived strain CJ- $S_{131}$  was purchased from Shanghai Health and Epidemic Prevention Station.

had been found, the possible mechanisms were studied from two aspects including inhibiting the expression of

ICAM-1 mRNA in ECV304 and accelerating apoptosis of

from the Chinese herb *Phytolacca esculenta*, is reported to possess several pharmacological effects including anti-inflammation and immunoregulation. The Chinese herb *Phytolacca esculenta* has been proved to have striking therapeutic effects on a number of diseases such as rheumatoid arthritis, edema, and tumor. EsA is the saponin which has the strong effects on acute and chronic inflammation in several kinds of models<sup>[1]</sup>. Moreover, EsA markedly inhibits humoral and cellular immunity such as diminishing production of antibody and lowering secretion of tumor necrosis factor (TNF), interleukin-1 (IL-1) and interleukin-6 (IL-6) by several kinds of cells, and diminishes function of over-activated macrophages such as phagorytosis and secretion of cytokines<sup>[2-7]</sup>. It is generally accepted that many immune cells and cytokines are involved in the occurrence and progress of autoimmune diseases. The previous results showed that EsA possessed therapeutic effect on an autoimmune disease, passive Heymann nephritis<sup>[8]</sup>. We supposed that EsA might have favorable effect in the

<sup>&</sup>lt;sup>2</sup> Correspondence to Dr XIAO Zhen-Yu.

Esculentoside A

Freund's complete adjuvant and PCR marker were obtained from Sino-American Biotechnology Company.  $^3\text{H-TdR}$  was obtained from Institute of Atomic Nucleus (Chinese Academy of Medical Sciences, Shanghai). Spin or vacuum (SV) total RNA isolation system kit and access RT-PCR system kit was purchased from Promega Corporation. Primers of ICAM-1 and  $\beta$ -actin were synthesized by Shanghai Sangon Corporation. Esculentoside A (purity >99 %) was provided by Prof YI Yang-Hua (Second Medical Miliuary University, Shanghai). Annexin v-fitc kit was purchased from Pharmingen Corporation.

Animal and cell line BABL/C mice, weighing 18-22~g, were from the Animal Center of Second Military Medical University (Grade [], Certificate No 02-25-7).

Human umbilical vein endothelial cell line ECV304 was obtained from Kenen Company, Beijing. The ECV304 cells were cultured in modified Eagle's medium (MEM; Gibco) containing 20 % fetal bovine serum (FBS; Gibco).

Animal model and drug treatment Murine model was established as follows: CJ-S<sub>131</sub> suspension  $[3 \times 10^{12} \text{ CFU (colony forming unit)/L}]$  was mixed with equivalent Freund's adjuvant complete. After full emulsifification, this emulsion (50  $\mu$ L) was injected into murine footplate. Two weeks later, the second injection was made in murine tail vein with 0.2 mL CI-S<sub>131</sub> suspension (3 × 10<sup>12</sup> CFU/L).

Thirty BALB/c mice were divided five groups (six mice in each group): the first group was normal mice, which were treated equal volume of normal saline instead of CJ-S<sub>131</sub> suspension in two injections. The control group was model mice, which were given equal volume of normal saline instead of EsA; the model mice in the rest three groups were given ip EsA at a dose of 5, 10, or 20 mg/kg respectively, once a day till four weeks after

the second injection.

At the end of the experiment, blood samples were centrifuged and plasma was kept at  $-20~^{\circ}\mathrm{C}$  until the assays were performed. The ankle joint was collected after the spleen was obtained in the aseptic condition.

Anti-ds DNA antibody The detection of anti-ds DNA antibody in the murine serum was performed as previously described<sup>(9)</sup>. In brief, ds DNA (0.25 µg/ well) was put into 96-well microplate for 24 h at 4 °C, and washed three times by PBS. The serum was diluted with PBS at 1:100 dilution, and this diluted serum (100 μL) was added into the well. Reaction was performed for 2 h at 37 °C. Coat anti-mouse IgG-HRP (1:2000 dilution) was added and kept for 2 h at 37 °C. Then 100 μL o-phenylenediamine solution was added and kept for 30 min at 37 °C, and 50 µL H<sub>2</sub>SO<sub>4</sub> solution was added to stop the reaction. The control well was added with PBS instead of the serum. The value of absorbance at 490 nm  $(A_{490})$  was examined. The experimental result was represented by enzyme index (EI). EI =  $[A_{490}]$  in experimental mouse/(mean  $A_{490}$  in normal mouse + 3  $SD) \times 100$ ].

**Splenocyte proliferation** Single cell suspension was prepared from murine spleen of each group. Spleen cells  $(1 \times 10^6/\text{well})$  were seeded in 96-well microplate for 72 h. Cells from each group were stimulated with ConA, LPS or without mitogen respectively. H-TdR (18 500 Bq/well) was added at 20 h before the end of culture. Cells were harvested after cultivation. The incorporation of  $^3\text{H-TdR}$  was determined and expressed as Bq.

Histological examination Ankle joints were obtained from killed mice and fixed with 10 % formalin solution for 24 h. The joints were decalcified with 10 % decalcifying fluid for 21 d. After full decalcification, joints were longitudinally cut open and were made into tissue sections. For histological examination, those sections were deparaffinized, hydrated, and stained with

hematoxylin and eosin according to standard procedures, then examined under the microscope.

Expression of ICAM-1 mRNA ECV304 cells at confluence were pretreated with serum-free MEM for 24 h. The medium was then replaced with fresh medium containing 1 mg/L lipopolysaccharide (LPS, Sigma), and cells were incubated for 6 h. Then EsA was added at concentrations of 2.5, 5, or 10 mg/L respectively. The cells were incubated for 24 h at 37 °C, and the total RNA was extracted according to SV total RNA isolation system kit. RT-PCR was performed according to access The sense primer sequence of RT-PCR system kit. ICAM-1 was 5'-TCT CGT GCC GCA CTG AAC TGG AC-3', and antisense primer was 5'-CCT TCT GAG ACC TCT GGC TTC GT-3'; the sense primer sequence of β-actin was 5'-GTG GGG CGC CCC AGG CAC CA-3', and antisense primer was 5'-CTC CTT AAT GTC ACG CAC GAT TTC-3'(10). The PCR was performed using the following parameters: 94 °C for 30 s, annealing at 58 °C for 1 min, and extension at 72 °C for 1.5 min. The cycle was repeated at 28 times. ICAM-1 mRNA was amplified and analyzed by electrophoresis in 1.5 % agarose gel. ICAM-1 mRNA was quantitated by computer digital scanning density image (Shanghai Sixing Biological Technology Co Ltd).

Thymocyte apoptosis Single thymocyte suspension was prepared from murine thymus and thymocytes ( $1\times10^6$  cells/flask) were added to five culture flasks respectively. A control group was treated with pure mediums. ConA (25~mg/L) was added into the rest groups, three groups of which were given simultaneously EsA at concentrations of 2.5, 5~or~10~mg/L respectively. They were incubated at 37~°C and harvested after 1.5~h.

Morphology analysis of thymocyte apoptosis was performed according to standard procedure. In brief, harvested thymocytes were fixed with 4 % para-formal-dehyde solution overnight. After potch with PBS, cells were fixed for 2 h. Thymocytes were washed with PBS and were after fixing with 1 % osmic acid for 2 h. Thymocytes were embeded with Epon812, polymerized, and sliced. The slices were stained with acetic uranium for 30 min and then with lead citrate for 30 min. These cells were observed under a Hitachi H-800 transmission electron microscope and photographed.

Apoptosis analysis by flow cytometry was performed according to Annexin v-fitc kit. In brief, harvested thymocytes were washed twice with PBS and diluted with

binding buffer. Dilution 100  $\mu L$  (1 × 10 $^{9}$  cells/L) were added 5  $\mu L$  Annexin v-fite and 2  $\mu L$  propidium iodide. The reaction went on 15 min in the darkness at room temperature (20 – 25  $^{\circ}$ C). Binding buffer 400  $\mu L$  was supplied into the solution. Thymocyte apoptosis was determined by flow cytometry.

**Statistics** Data were expressed as  $\bar{x} \pm s$ . Each experiment was repeated at least three times. Differences were considered statistically significant when P < 0.05 as analyzed by ANOVA and unpaired t-test.

#### RESULTS

Effects of EsA on the level of anti-ds DNA antibody The anti-ds DNA antibody increased markedly in the serum of model mice (P < 0.01). EsA effectively lowered the level of anti-ds DNA antibody in the serum of model mice in a dose-dependent manner. At the dose of EsA 20 mg/kg, the level of anti-ds DNA antibody was close to the normal (Tab 1).

Tab 1. Effect of EsA on the level of anti-ds DNA antibody. n = 6.  $\hat{x} \pm s$ .  $^cP < 0.01$  vs normal group.  $^tP < 0.01$  vs control group.

| 0.70 - 0.04                  |                                                                       |
|------------------------------|-----------------------------------------------------------------------|
| $0.70 \pm 0.04$              | $85 \pm 5$                                                            |
| $1.03 \pm 0.15^{\circ}$      | $125 \pm 18^{\circ}$                                                  |
| $0.91 \pm 0.06^{f}$          | $110 \pm 7^{f}$                                                       |
| $0.80 \pm 0.06^{f}$          | $97 \pm 7^{f}$                                                        |
| $0.71 \pm 0.11^{\mathrm{f}}$ | $86 \pm 13^{f}$                                                       |
|                              | $1.03 \pm 0.15^{\circ}$<br>$0.91 \pm 0.06^{f}$<br>$0.80 \pm 0.06^{f}$ |

## Effects of EsA on splenocyte proliferation

In model mice, the proliferation of splenocyte cells was distinct from that in normal mice whether stimulated with ConA, LPS or without mitogen. Cell proliferation was decreased dose-dependently by EsA. When no mitogen, the inhibitory rate of EsA at the dose of 5, 10, and 20 mg/kg was 26 %, 33 %, and 42 % respectively ( P < 0.01). When splenocytes were stimulated with ConA, cell proliferation was close to the normal at the dose of EsA 10 mg/kg. However, when mitogen was LPS, cell proliferation was close to the normal at the dose of EsA 20 mg/kg (Tab 2).

Effects of EsA on inflammation of joint Synovial pannus appeared in the ankle joint of model mouse. Synovium was heavily infiltrated with inflammatory cells and cartilage adjacent to synovial pannus

Tab 2. Effects of EsA on splenocyte proliferation. n = 6.  $x \pm s$ .  $^cP < 0.01$  vs normal group.  $^tP < 0.01$  vs control group.

| Group                     | Splenocyte proliferation/Bq |                      |                    |
|---------------------------|-----------------------------|----------------------|--------------------|
|                           | No mitogen                  | ConA                 | LPS                |
|                           |                             |                      |                    |
| Normal                    | $9.4 \pm 2.5$               | $182 \pm 46$         | $28 \pm 4$         |
| Control                   | $66 \pm 7^{c}$              | $405 \pm 65^{\circ}$ | 86 ± 11°           |
| EsA/mg·kg <sup>-1</sup> 5 | $27 \pm 6^f$                | $281 \pm 40^{f}$     | $67 \pm 8^{f}$     |
| 10                        | $21.6 \pm 2.6^{\circ}$      | 179±6 <sup>5</sup>   | $53 \pm 9^{6}$     |
| 20                        | $17 \pm 4^{\circ}$          | $76 \pm 12^{f}$      | $28 \pm 3^{\circ}$ |

was degraded. The bigger the dose of EsA was, the more remittent the inflammation of ankle joint became. When the dose of EsA was minor, synovial pannus decreased and cartilage could be seen. When the dose of EsA reached 20 mg/kg, the formation of synovial pannus was inhibited significantly and the intact cartilage could be seen. The result showed the inflammation was ameliorated markedly by EsA (Fig 1).

Effects of EsA on expression of ICAM-1 mRNA When the ECV304 cell was stimulated by LPS, the expression of ICAM-1 mRNA increased approximately two times. This increased expression was remarkably attenuated by the addition of EsA. The ratio of ICAM-1/β-actin mRNA from lane 1 to lane 5 was 0.472, 0.814, 0.693, 0.615, 0.563, respectively (Fig 2). The result indicated that the enhanced expression of

ICAM-1 mRNA by LPS in the ECV304 cell was decreased by EsA.

## Effects of EsA on thymocyte apoptosis

Thymocytes activated by ConA showed characteristic alteration of cell morphology of apoptosis, namely cell shrinkage, plasma membrane blebbing, and nuclear After these cells were given EsA, condensation. apoptosis of activated thymocyte had an accelerated trend. Thymocytes were treated with EsA at the concentration of 10 mg/L and then apoptosis body appeared. This result preliminarily indicated that EsA could accelerate apoptosis of thymocyte activated by ConA (Fig 3). To conform this effect of EsA, we analyzed apoptosis of thymocyte by flow cytometry. It is found that the ratio of apoptosis of thymocyte activated by ConA was approximately 4 times higher than that in the normal thymocyte. When the activated thymocytes were given EsA at the concentration of 10 mg/L, the ratio of apoptosis of thymocyte was approximately two times higher than that in the activated thymocytes. EsA markedly accelerated apoptosis of thymocyte activated by ConA (Fig 4).

#### DISCUSSION

Chinese people have utilized the herb *Phytolacca* esculenta for the therapy of various diseases for more than a thousand year. Some of these diseases belong to autoimmune disease. The previous report showed that




Fig 1. Effects of EsA on inflammation of joint through analysis of pathologic section. (A) normal; (B) model; (C) model mice treated with EsA 10 mg/kg; (D) model mice treated with EsA 20 mg/kg. ×100.




Fig 2. Expression of ICAM-1 mRNA after treatment with EsA. Lane M: DNA marker; Lane 1: control; Lane 2: EVC304 stimulated by LPS; Lane 3: EVC304 stimulated by LPS and treated with EsA 2.5 mg/L; Lane 4: EVC304 stimulated by LPS and treated with EsA 5 mg/L; Lane 5: EVC304 stimulated by LPS and treated with EsA 10 mg/L.




Fig 3. Effect of EsA on apoptosis on murine thymocyte by electronic microscope (A) thymocyte; (B) thymocyte activated by ConA; (C) thymocyte activated by ConA and treated with EsA 2.5 mg/L; (D) thymocyte activated by ConA and treated with EsA 10 mg/L.  $\times$  10 000.

passive Heymann nephritis, an autoimmune disease, could be cured by EsA<sup>[8]</sup>. In this study we determined the effects of EsA on autoimmunity in a mouse model.

The autoimmunity model was established through immunizing mice with formaldehyde treated *Campyl-obacter jejuni* strain CJ-S<sub>131</sub> and Freund's complete adjuvant, which have some characteristics of autoimmu-




Fig 4. Effect of EsA on apoptosis of murine thymocyte activated by ConA through FACS analysis. (LR was ratio of thymocyte apoptosis). 001: normal thymocyte. 002: thymocyte activated by ConA. 003: thymocyte activated by ConA and treated with EsA 2.5 mg/L. 004: thymocyte activated by ConA treated with EsA 5 mg/L. 005: thymocyte activated by ConA treated with EsA 10 mg/L.

nity such as high level of autoantibodies in serum, hyperactivity of T and B cells, and inflammatory injuries in multiple organs. This model has been recognized to be very useful for studying the mechanism of autoimmunity and screening the immunoregulators<sup>[11]</sup>. To an autoimmune disease, the importance of autoantibodies as diagnostic markers has been demonstrated by the pioneering studies of Eng Tan<sup>[12]</sup>. The major cellular

The present study showed that EsA could lower the high level of anti-ds DNA antibody and inhibit the hyperactivity of T and B cells in a dose-dependent manner. It suggested that EsA might ameliorate symptom of autoimmune rheumatic disease such as rheumatoid arthritis through the inhibition of autoantibody production and lymphocyte proliferation. In the experiment of splenocyte proliferation, we found that EsA 10 mg/kg decreased splenocyte proliferation to the normal when splenocytes were stimulated with ConA. However, EsA 20 mg/kg could get to the same effect when mitogen was LPS. It suggested that EsA might have stronger effect on T cells than B cells.

In the joint of model mouse appeared the trilogy of rheumatoid arthritis: proliferation of inflammation, and destruction of cartilage. Those symptoms had been strongly ameliorated after treatment with EsA. T cells can produce many pro-inflammatory cytokines such as TNF, IL-1, and IL-6. IL-1 and TNF are major cytokines which can lead to the inflammation of synovitis and destruction of cartilage<sup>(15)</sup>. Recombinant antagonist of IL-1 receptor and monoclonal antibody of TNF had shown good effect in the therapy of rheumatoid arthritis (16,17). EsA can inhibit the production of IL-1 and TNF from synovial cell<sup>(4)</sup>. Therefore, EsA might ameliorate the trilogy of rheumatoid arthritis through influencing the production of cytokines. The present study testified that EsA could have good effects on autoimmune disease such as rheumatoid arthritis.

To further investigate the mechanism of EsA on autoimmunity, we examined the apoptosis of activated thymocyte and expression of ICAM-1 mRNA by

EVC304. It is well known that activated T cells play a very important role in the pathology of autoimmune disease<sup>(18)</sup>. T cells existed widely in the pannus of rheumatoid arthritis. In the clinic practise, this disease can be cured through decreasing the quantity of T cells such as drainage through alimentary duct or irradiation of lymphoid tissue. EsA has been showed to markedly inhibit humoral immunity<sup>(2)</sup>. The present result suggested that EsA might inhibit cellular immunity since it could accelerate the apoptosis of activated thymocyte. Therefore, EsA may be favorable for autoimmune disease such as rheumatoid arthritis through the inhibition of immunity.

Adhesion molecules are very important because adhesion molecule expression and interactions are probably involved in initiation and propagation of autoimmune diseases including rheumatoid arthritis (RA), systemic lupus erythematosus, Sjogren's syndrome, autoimmune thyroid disease, multiple sclerosis, and diabetes mellitus. In rheumatoid arthritis, adhesion molecules can lead to lymphocyte infiltration of joint and inflammation. ICAM-1 plays a pivotal role in the activation and close adhesion of leucocyte, which is the most important step in the exudation of inflammatory cell<sup>[19]</sup>. EsA decreased expression of ICAM-1 mRNA. which suggested that the inhibition of adhesion molecules might be one of the mechanisms of anti-inflammation of EsA.

In summary, our study clearly demonstrated that EsA had the positive curative effect on the autoimmunity in a mouse model, which may function through anti-inflammation and inhibitory effect on immune system. These pharmacological effects of EsA strongly suggested its potential therapeutic role to the autoimmune disease such as rheumatoid arthritis. Therefore, it is deserved that we pay close attention to EsA, a hopeful prodrug to autoimmune disease.

#### REFERENCES

- Zheng QY, Mai K, Pan XF, Yi YH. Anti-inflammatory effects of esculentoside A. Chin J Pharmacol Toxicol 1992; 6: 221-4.
- 2 Ju DW, Zheng QY, Wang HB, Guan XG, Fang J, Yi YH. Inhibitory effects of esculentoside A on mouse macrophages and antibody production. Acta Pharm Sin 1994; 29; 252 – 5.
- 3 Fang J, Zheng QY. Inhibitory effects of esculentoside A on platelet activating factor released from calcimycin induced rat peritoneal macrophages. Acta Pharm Sin 1991; 26: 721-4.
- 4 Zheng QY, Wang HF, Zheng XM, Xiao ZY, Yi YH.

- Effects of esculentoside A on production of IL-1 and TNF by rabbit synovial cells. Acad J Second Mil Med Univ 2001; 22:425-6.
- 5 Zheng QY, Fang J, Wang HB. Inhibitory effect of esculentoside A on TNF production by human monocytes. Acad J Second Mil Med Univ 1997; 18: 415 – 7.
- 6 Fang J, Zheng QY, Wang HB. The effect of esculentoside A on the release of TNF from murine macrophage. Mediators of Inflammation 1992; 1: 375 ~ 7.
- 7 Ju DW, Zheng QY, Cao X, Fang J, Wang HB. Esculentoside A inhibits tumor necrosis factor, interleukin-1 and interleukin-6 production induced by lipopolysaccharide in mice. Pharmacology 1998; 56; 187 – 94.
- 8 Ju DW, Zheng QY, Wang HB, Guan XJ, Fang J, Yi YH. Therapeutic effects of esculentoside A on passive Heymann nephritis in rats and its inhibition on cytokine production. Acta Pharm Sin 1999;34: 9-12.
- 9 Moncef ZB, David S. A rapid ELISA for measurement of antibodies to nucleic acid antigens using UV-treated polystyrene microplates. J Immunol Methods 1986; 90; 105-10.
- 10 Guo FK, Li YL, Wu SG. Inhibition of antisense IRAK-2 oligodeoxynucleotide on the biological effects of interleukin-1. Chin Pharm J 2000; 35: 52-5.
- 11 Sun B, Ma BL, Xie YL. An animal model of autoimmunity induced by formaldehyde treated CJ-S<sub>131</sub> and Freund's complete adjuvant. Shanghai J Immunol 1991; 11; 257-60.
- 12 Reeves WH, Satoh M. Features of autoantigens. Mol Biol Rep 1996; 23; 217 – 26.
- 13 Hietarinta M, Lassila O. Clinical significance of antinuclear antibodies in systemic rheumatic diseases. Ann Med 1996; 28: 283 – 91.
- 14 van Laar JM, Miltenburg AM, Verdonk MJ, Leow A, Elferink BG, Daha MR, et al. Activated synovial T cell clones from a patient with rheumatoid arthritis induce proliferation of autologous peripheral blood-derived T cells. Cell Immunol 1993; 146; 71-9.
- 15 Vandberg WB, Joosten LA, Vandeloo FA. TNF alpha and IL-1 beta are separate targets in chronic arthritis. Clin Exp Rheumatol 1999; 17 (6 Suppl 18); S105-14.
- 16 Taylor PC. Anti-tumor necrosis factor therapies. Curr Opin Rheumatol 2001; 13: 164-9.
- 17 Dayer JM, Feige U, Edwards CK, Burger D. Antiinterleukin-1 therapy in rheumatic diseases. Curr Opin Rheumatol 2001; 13; 170-6.

- 18 Breedveld FC, Struyk L, van Laar JM, Miltenburg AM, de Vries RR, van den Elsen PJ. Therapeutic regulation of T cells in rheumatoid arthritis. Immunol Rev 1995; 144: 5 – 16
- 19 McMurray RW. Adhesion molecules in autoimmune disease. Semin Arthritis Rheum 1996; 25: 215 – 33.

# 商陆皂苷甲对自身免疫性模型小鼠的影响及其作用 机制<sup>1</sup>

# R96 A

肖振宇<sup>2</sup>,郑钦岳,张俊平,姜远英,易杨华<sup>3</sup> (第二军医大学药学院药理教研室,<sup>3</sup>天然药化教研室,上海 200433,中国)

**关键词** 商陆皂苷甲; 自身免疫; 炎症; 细胞间粘附分子-1; 细胞凋亡; 类风湿性关节炎

目的:考察商陆皂苷甲对自身免疫性模型小鼠的影响及其可能的机制.方法:自身免疫性小鼠模型通过甲醛化空弯菌 CJ-Slai辅以佐剂免疫小鼠获得.检测正常小鼠、模型小鼠及商陆皂苷甲处理的模型小鼠血清中的抗 ds DNA 抗体水平、细胞增殖及骨类节病理切片.通过形态学和流式细胞仪检测胸腺细胞,通过逆转录 PCR 的方法检测 ECV304 细胞中 ICAM-1 的 mRNA 表达.结果:商陆皂苷甲能力 值别 在 医CV304 细胞中 ICAM-1 的 mRNA 表达.结论:商陆皂苷甲对自身免疫性模型小鼠有治疗作用;促进胸腺细胞调亡和降低 ECV304 细胞中 ICAM-1 的 mRNA 表达可能是其作用的重要机制.

(责任编辑 韩向晖)